Showing results (571-580 of 9,668) with videos related to

Sort By:
Pageof 967
Leukemia|September 24, 2010
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaE Jabbour, M Deininger, A Hochhaus
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Leukemia|February 26, 2011
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myelomaK Detweiler Short, S V Rajkumar, D Larson, et al.
Leukemia|January 22, 2011
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemiaS S Farag, L L Wood, J E Schwartz, et al.
Leukemia|January 22, 2011
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaB Paiva, M Pérez-Andrés, M-B Vídriales, et al.
Leukemia|January 8, 2011
E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemiaI Saborit-Villarroya, T Vaisitti, D Rossi, et al.
Leukemia|January 19, 2011
LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathwayH Hasegawa, Y Yamada, K Tsukasaki, et al.
Leukemia|January 19, 2011
The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trialV Zachariadis, F Gauffin, E Kuchinskaya, et al.
Leukemia|January 15, 2011
The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemiaB Pless, C Oehm, S Knauer, et al.
Leukemia|January 15, 2011
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effectI Cristóbal, L Garcia-Orti, C Cirauqui, et al.
Pageof 967